Search Results - "The New England Journal of Medicine"

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia by Burger, Jan A, Tedeschi, Alessandra, Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Bairey, Osnat, Hillmen, Peter, Bartlett, Nancy L, Li, Jianyong, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A, Janssens, Ann, Offner, Fritz, Mayer, Jiří, O’Dwyer, Michael, Hellmann, Andrzej, Schuh, Anna, Siddiqi, Tanya, Polliack, Aaron, Tam, Constantine S, Suri, Deepali, Cheng, Mei, Clow, Fong, Styles, Lori, James, Danelle F, Kipps, Thomas J

“…The Bruton's tyrosine kinase inhibitor ibrutinib was compared with the alkylating agent chlorambucil in patients with chronic lymphocytic leukemia. Ibrutinib…”
Get full text

Lecanemab in Early Alzheimer’s Disease by van Dyck, Christopher H., Swanson, Chad J., Aisen, Paul, Bateman, Randall J., Chen, Christopher, Gee, Michelle, Kanekiyo, Michio, Li, David, Reyderman, Larisa, Cohen, Sharon, Froelich, Lutz, Katayama, Sadao, Sabbagh, Marwan, Vellas, Bruno, Watson, David, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn D., Iwatsubo, Takeshi

“…In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and…”
Get full text

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity by Siegal, Deborah M, Curnutte, John T, Connolly, Stuart J, Lu, Genmin, Conley, Pamela B, Wiens, Brian L, Mathur, Vandana S, Castillo, Janice, Bronson, Michele D, Leeds, Janet M, Mar, Florie A, Gold, Alex, Crowther, Mark A

“…The new oral anticoagulants have many advantages over warfarin, but one disadvantage is the inability to rapidly reverse their anticoagulant effects…”
Get full text

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis by Baeten, Dominique, Sieper, Joachim, Braun, Jürgen, Baraliakos, Xenofon, Dougados, Maxime, Emery, Paul, Deodhar, Atul, Porter, Brian, Martin, Ruvie, Andersson, Mats, Mpofu, Shephard, Richards, Hanno B

“…In two placebo-controlled phase 3 trials, secukinumab, an anti–interleukin-17A monoclonal antibody, was effective in patients with ankylosing spondylitis…”
Get full text

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer by Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas

“…Patients with non–small-cell lung cancer were randomly assigned to three cycles of chemotherapy with or without nivolumab, an anti–PD-1 antibody. Event-free…”
Get full text

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes by Lincoff, A. Michael, Brown-Frandsen, Kirstine, Colhoun, Helen M., Deanfield, John, Emerson, Scott S., Esbjerg, Sille, Hardt-Lindberg, Søren, Hovingh, G. Kees, Kahn, Steven E., Kushner, Robert F., Lingvay, Ildiko, Oral, Tugce K., Michelsen, Marie M., Plutzky, Jorge, Tornøe, Christoffer W., Ryan, Donna H.

“…In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major…”
Get full text

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis by Curry, Michael P, O’Leary, Jacqueline G, Bzowej, Natalie, Muir, Andrew J, Korenblat, Kevin M, Fenkel, Jonathan M, Reddy, K. Rajender, Lawitz, Eric, Flamm, Steven L, Schiano, Thomas, Teperman, Lewis, Fontana, Robert, Schiff, Eugene, Fried, Michael, Doehle, Brian, An, Di, McNally, John, Osinusi, Anu, Brainard, Diana M, McHutchison, John G, Brown, Robert S, Charlton, Michael

“…In this phase 3 study involving patients with HCV genotype 1, 2, 3, 4, or 6 and decompensated cirrhosis, sofosbuvir–velpatasvir with or without ribavirin for…”
Get full text

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection by Foster, Graham R, Afdhal, Nezam, Roberts, Stuart K, Bräu, Norbert, Gane, Edward J, Pianko, Stephen, Lawitz, Eric, Thompson, Alex, Shiffman, Mitchell L, Cooper, Curtis, Towner, William J, Conway, Brian, Ruane, Peter, Bourlière, Marc, Asselah, Tarik, Berg, Thomas, Zeuzem, Stefan, Rosenberg, William, Agarwal, Kosh, Stedman, Catherine A.M, Mo, Hongmei, Dvory-Sobol, Hadas, Han, Lingling, Wang, Jing, McNally, John, Osinusi, Anu, Brainard, Diana M, McHutchison, John G, Mazzotta, Francesco, Tran, Tram T, Gordon, Stuart C, Patel, Keyur, Reau, Nancy, Mangia, Alessandra, Sulkowski, Mark

“…In two phase 3 trials involving patients with hepatitis C virus infection, including those with cirrhosis, 12 weeks of sofosbuvir–velpatasvir resulted in a…”
Get full text

Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine by Lee, Peter, Bubeck, Sebastien, Petro, Joseph

“…Chatbots are computer programs with which one can have a conversation. In this article, the authors describe how the GPT-4 chatbot, which has been given a…”
Get full text

Once-Weekly Semaglutide in Adults with Overweight or Obesity by Wilding, John P.H, Batterham, Rachel L, Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F, Lingvay, Ildiko, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie T.D, Wadden, Thomas A, Wharton, Sean, Yokote, Koutaro, Zeuthen, Niels, Kushner, Robert F

“…This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68…”
Get full text

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Sartor, Oliver, de Bono, Johann, Chi, Kim N, Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T, Nordquist, Luke T, Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H, Beer, Tomasz M, Armour, Alison, Pérez-Contreras, Wendy J, DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A, Morris, Michael J, Krause, Bernd J

“…Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus…”
Get full text

Dapagliflozin in Patients with Chronic Kidney Disease by Heerspink, Hiddo J.L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E, McMurray, John J.V, Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C

“…In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome —…”
Get full text

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 by Mégarbane, Bruno

Get full text

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma by Locke, Frederick L, Miklos, David B, Jacobson, Caron A, Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O, Ghobadi, Armin, Rapoport, Aaron P, McGuirk, Joseph, Pagel, John M, Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M, Sureda, Anna, Flinn, Ian W, Vandenberghe, Peter, Song, Kevin W, Dickinson, Michael, Minnema, Monique C, Riedell, Peter A, Leslie, Lori A, Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I, Westin, Jason R

“…In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer…”
Get full text

Clinical Characteristics of Covid-19 in China. Reply by Guan, Wei-Jie, Zhong, Nan-Shan

Get full text

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis by Gillmore, Julian D, Gane, Ed, Taubel, Jorg, Kao, Justin, Fontana, Marianna, Maitland, Michael L, Seitzer, Jessica, O’Connell, Daniel, Walsh, Kathryn R, Wood, Kristy, Phillips, Jonathan, Xu, Yuanxin, Amaral, Adam, Boyd, Adam P, Cehelsky, Jeffrey E, McKee, Mark D, Schiermeier, Andrew, Harari, Olivier, Murphy, Andrew, Kyratsous, Christos A, Zambrowicz, Brian, Soltys, Randy, Gutstein, David E, Leonard, John, Sepp-Lorenzino, Laura, Lebwohl, David

“…A lipid nanoparticle containing mRNA for Cas9 protein and a single guide RNA targeting TTR was infused with the goal of insertion into hepatocytes and blocking…”
Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

“…Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival…”
Get full text

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer by Kelly, Ronan J, Ajani, Jaffer A, Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine, Motoyama, Satoru, Lièvre, Astrid, Uronis, Hope, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen, Zafar, Syed, Snow, Stephanie, Ko, Andrew H, Feeney, Kynan, Schenker, Michael, Kocon, Piotr, Zhang, Jenny, Zhu, Lili, Lei, Ming, Singh, Prianka, Kondo, Kaoru, Cleary, James M, Moehler, Markus

“…Adjuvant chemotherapy has not improved disease-free survival among patients with resected esophageal or gastroesophageal junction cancer. In this trial, after…”
Get full text

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer by Wu, Yi-Long, Tsuboi, Masahiro, He, Jie, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu-Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

“…The incidence of recurrence after curative resection among patients with stage IB, II, or IIIA non–small-cell lung cancer is high and is only slightly lower…”
Get full text

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation by Kirchhof, Paulus, Camm, A. John, Goette, Andreas, Brandes, Axel, Eckardt, Lars, Elvan, Arif, Fetsch, Thomas, van Gelder, Isabelle C, Haase, Doreen, Haegeli, Laurent M, Hamann, Frank, Heidbüchel, Hein, Hindricks, Gerhard, Kautzner, Josef, Kuck, Karl-Heinz, Mont, Lluis, Ng, G. Andre, Rekosz, Jerzy, Schoen, Norbert, Schotten, Ulrich, Suling, Anna, Taggeselle, Jens, Themistoclakis, Sakis, Vettorazzi, Eik, Vardas, Panos, Wegscheider, Karl, Willems, Stephan, Crijns, Harry J.G.M, Breithardt, Günter

“…In this multicenter, randomized trial comparing early rhythm control with usual care in patients with early atrial fibrillation and cardiovascular conditions,…”
Get full text